Navigation Links
Genzyme Reports Strong Second-Quarter Growth
Date:7/23/2008

uctive quarter," said Henri A. Termeer, Genzyme's chairman and chief executive officer. "We delivered solid financial results, set in place a number of catalysts that will drive near-term growth, and continued to build the company to grow beyond 2011."

Over the next 12 months, Genzyme anticipates six potential approvals for new products or broader indications for existing products. These catalysts will provide significant near term momentum:

-- Genzyme expects FDA approval by the end of this year for alglucosidase alfa (Myozyme(R)) produced at the 2000L bioreactor scale, following the submission of a BLA on May 30. European approval of Myozyme produced at the 4000L scale is expected in the first half of next year.

-- The company anticipates that the labeling for Renvela(R) (sevelamer carbonate) will be expanded by mid-2009 to include the treatment of chronic kidney disease patients with elevated phosphorus levels who are not on dialysis. Genzyme, along with two other companies, submitted a position paper to the FDA in May regarding this expanded use of phosphate binders.

-- Genzyme also expects that the labeling for Clolar(R) (clofarabine) will be expanded by the middle of next year to include its use in treating adult patients with acute myelogenous leukemia. The company plans to file supplemental marketing applications this year to broaden Clolar's indication.

-- Genzyme expects to launch Mozobil(TM) (plerixafor) in the United States and Europe during the first half of next year, following regulatory approval. The company submitted marketing applications for the product last month. Mozobil is intended to enable patients with certain types of cancers to successfully receive a stem-cell transplantation.

-- FDA action on Genzyme's marketing application for Synvisc-ONE(R) (hylan G-F 20) is anticipated this year. The company submitted a response to the agency in June that included additional analysis and data requested in a Nov
'/>"/>

SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Genzyme Begins Major Expansion of Boston Manufacturing Facility
3. Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
4. Genzyme Receives Approval to Market Elaprase(R) in Japan
5. Genzyme Recognized by Scientists as a Top Employer
6. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. Genzyme Launches Cholestagel(R) in Europe
9. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 ... to announce the appointment of John P. Donoghue ... Biotech   in  Geneva . The ... Campus Biotech in Geneva , has ... recognised neuroscientists. John P. Donoghue , founder of ...
(Date:7/11/2014)... 11, 2014  Researchers have pioneered a revolutionary ... new technology, called Virtual Finger, allows scientists to ... neurons and synapses using the flat surface of ... 3D imaging studies orders of magnitude more efficient, ... level across many areas of experimental biology. The ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Women ... have access to an additional family planning option. ... to contraception at all levels of the health ... formulation of a widely used contraceptive—Pfizer’s Depo-Provera® (depot ... Burkina Faso is the first of four African ...
(Date:7/10/2014)... 10, 2014 Deep Knowledge Ventures ... Forum on ‘Commercialising Longevity Research’ and welcomed a ... the London Bioscience Innovation Center for the event, ... Aging Analytics Ltd. The meeting highlighted the need ... research for age-related disease, as well as the ...
Breaking Biology Technology:John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6
... of dementia ... and participation in clinical trials., Silicon Valley,s Conway, Campbell ... Internet to Transform Medical Research and Philanthropic Outreach, ... of,California, San Francisco (UCSF) today launched a comprehensive Internet,video ...
... Life Sciences Inc.,(TSX: PLI) ("ProMetic") today presented ... trial in patients with chemotherapy-induced,anemia ("CIA") at ... Association,held in Copenhagen, Denmark this week., ... presented data on,PBI-1402 in a poster entitled ...
... VANCOUVER, June 13 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. (NASDAQ: ... pharmaceutical and,medical device company, today announced the market ... available immediately for distribution,and sale in the U.S. ... made from a rapidly resorbing,polymer, is intended primarily ...
Cached Biology Technology:UCSF and YouTube Launch Channel Dedicated to Educating the Public About Neurodegenerative Diseases 2UCSF and YouTube Launch Channel Dedicated to Educating the Public About Neurodegenerative Diseases 3Positive clinical data for PBI-1402 presented at the Annual Congress of the European Hematology Association 2Positive clinical data for PBI-1402 presented at the Annual Congress of the European Hematology Association 3Angiotech announces market launch of Quill(TM) SRS MONODERM(TM) 2Angiotech announces market launch of Quill(TM) SRS MONODERM(TM) 3Angiotech announces market launch of Quill(TM) SRS MONODERM(TM) 4
(Date:7/11/2014)... started near the City of Entiat on Tuesday, July ... fire quickly grew to over 1,000 acres by evening. ... is under investigation by the Washington Department of Natural ... local resources in developing fire control strategies and tactics. ... State Department of Natural Resources, (WA DNR), Bureau of ...
(Date:7/11/2014)... scientists have set a "mouse TRAP" to capture the ... recent study published in the Journal of Clinical ... technique called TRAP to extract cellular and genetic information ... scientists at the Rockefeller Institute for Medical Research in ... protein-making machinery, or ribosomes, of the cell type of ...
(Date:7/11/2014)... group members to reduce aggression and gain access to ... grooming activities shows a certain pattern across the day. ... Biology Letters . , Grooming between individuals in ... motives. To be groomed has hygienic benefits and is ... can provide access to infants, mating opportunities and high ...
Breaking Biology News(10 mins):Baboons groom early in the day to get benefits later 2
... almost 30 years, researchers have sought to identify a ... during photosynthesis. A team at Ludwig-Maximilians-Universitt (LMU) in Munich ... to be an old acquaintance. Photosynthesis sustains ... molecular oxygen that higher organisms depend on. The process ...
... Marine resource managers often gauge the health of species ... relationships in the Bering Sea found that it isn,t the ... how densely they are aggregated. It,s more than searching ... balance how much energy they expend in searching for food ...
... make animals, well, brainier, but that boost in brain size ... evidence reported on January 3rd in Current Biology , ... for large and small brain sizes. The findings lend ... ability do go together, a topic that has been a ...
Cached Biology News:Photosynthesis: The last link in the chain 2Bering Sea study finds prey density more important to predators than biomass 2Bering Sea study finds prey density more important to predators than biomass 3Big brains are pricey, guppy study shows 2
This antibody detects an ~25 kDa band, corresponding to the expected molecular mass of Rab3A, on immunoblots. The antibody specificity is confirmed in peptide inhibition immunoblotting studies....
HLA II DG+DR+DP Monoclonal Antibody, Purified, Unconjugated, Clone: IQU9 This antibody is specific for the monomorphic determinant of the HLA Class II beta chains of the human MHC (28 kDa)....
Anti-gp120/160(SIV/mac239) Immunogen: gp120(SIV/mac239) protein (Genebank accession #M33262)...
Phospho-MEF2A(Thr312)...
Biology Products: